Indications
Donanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology (see section 4.4).
Composition
- Active substance
- donanemab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kisunla
- Active substance
- donanemab
- ATC code
- N06DX05
- Group
- Nervous system
- Therapeutic area
- Alzheimer Disease, Cognitive Dysfunction
- Marketing authorisation holder
- Eli Lilly Nederland B.V.